

## GILENYA (fingolimod) [preferred] PRIOR AUTHORIZATION FORM

Prior authorization guidelines for Gilenya are located in the Medical Assistance Prior Authorization of Pharmaceutical Services Handbook Chapter – **Multiple Sclerosis Agents** and **Quantity Limits/Daily Dose Limits** accessible at <http://www.dhs.pa.gov/provider/pharmacyservices/index.htm>.

PRIOR AUTHORIZATION REQUEST INFORMATION		PRESCRIBER INFORMATION	
<input type="checkbox"/> New request	<input type="checkbox"/> Renewal request	total pages: _____	Prescriber name:
Name of office contact:		Specialty:	
Contact's phone number:		State license:	NPI:
RECIPIENT INFORMATION		Street address:	
Recipient Name:		Suite #:	City/state/zip:
Recipient ID#:	DOB:	Phone:	Fax:

### CLINICAL INFORMATION

<b>Medication requested:</b> Gilenya capsule	<b>Strength:</b>	<b>Quantity:</b>	<b>Refills:</b>
<b>Directions:</b>	<b>Diagnosis:</b>	<b>Dx code (required):</b>	
1. Which Specialty Pharmacy will be used?	<input type="checkbox"/> Diplomat Specialty Pharmacy	<input type="checkbox"/> Walgreen's Specialty Pharmacy	
2. Does the recipient have a diagnosis of a relapsing form of multiple sclerosis?	<input type="checkbox"/> Yes – <i>Submit documentation of diagnosis.</i>		
	<input type="checkbox"/> No – <i>Submit documentation supporting the use of Gilenya for the recipient's diagnosis.</i>		
3. Is the requested medication prescribed by a neurologist?	<input type="checkbox"/> Yes		
	<input type="checkbox"/> No – specialty: _____		
4. Did the recipient experience any of the following conditions in the past 6 months? <input type="checkbox"/> myocardial infarction <input type="checkbox"/> stroke or TIA <input type="checkbox"/> decompensated heart failure <input type="checkbox"/> unstable angina <input type="checkbox"/> Class III or IV heart failure    resulting in hospitalization	<input type="checkbox"/> Yes <i>Submit documentation.</i> <input type="checkbox"/> No		
5. Does the recipient have a baseline QTc interval ≥ 500 milliseconds?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
6. Does the recipient have AV block or sick sinus syndrome without a pacemaker?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
7. Is the recipient taking an anti-arrhythmic drug (eg, amiodarone, sotalol, dofetilide, quinidine)?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit medication list.</i>		
8. Is the recipient receiving concomitant therapy with antineoplastic, immunosuppressive, or immune modulating therapies?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit medication list.</i>		
9. Does the recipient have evidence of active infection?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
Initial requests			
1. Does the recipient have results of a recent (within the past 6 months) CBC with differential?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
2. Does the recipient have results of recent (within the past 6 months) liver function tests (LFTs)?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
3. Did the recipient have an EKG in the past 3 mos with no evidence of heart block or bradycardia?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
4. Did the recipient have a baseline (within past 3 months) ophthalmologic exam of the macula?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
5. Does the recipient have documentation of positive antibodies to varicella zoster virus (VZV)?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
6. Did the recipient receive a varicella zoster virus vaccine in the past one month?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
7. Will the recipient be observed in a medical facility for at least 6 hours after the 1 <sup>st</sup> dose to monitor for signs and symptoms of bradycardia as recommended in the package labeling?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
8. Will the recipient have a repeat EKG performed 6 hours after the 1 <sup>st</sup> dose of Gilenya?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
Renewal requests			
1. Did the recipient experience improvement or stabilization of the signs and symptoms of multiple sclerosis since starting Gilenya?	<input type="checkbox"/> Yes <i>Submit documentation of recipient's response to therapy.</i> <input type="checkbox"/> No		
2. Does the recipient have results of recent liver function tests (LFTs)?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
3. Does the recipient have results of a recent complete blood count (CBC) with differential?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
4. Did the recipient have an ophthalmologic exam of the macula 3-4 months after starting Gilenya?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i>		
5. <b>For recipients with a history of diabetes or uveitis</b> , did the recipient have annual ophthalmologic exams of the macula (in addition to the exam performed 3-4 months after starting Gilenya)?	<input type="checkbox"/> Yes <input type="checkbox"/> No <i>Submit documentation.</i> <input type="checkbox"/> Not applicable		

**PLEASE FAX COMPLETED FORM WITH REQUIRED CLINICAL DOCUMENTATION TO DHS – PHARMACY DIVISION**

<b>Prescriber Signature:</b>	<b>Date:</b>
------------------------------	--------------

**Confidentiality Notice:** The documents accompanying this telecopy may contain confidential information belonging to the sender. The information is intended only for the use of the individual named above. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or taking of any telecopy is strictly prohibited.